Among patients with established atherothrombotic disease, the use of antiplatelets, beta-blockers, ACE inhibitors, or ARBs or statins was higher in developed countries (average adherence > 50%), and lower in the countries presenting lower average income (average adherence < 10%). The gene discussed is ACE; the disease is glycogen storage disease VI.